Drug Profile
Research programme: phosphodiesterase inhbitors - Intra-Cellular Therapies
Alternative Names: ITI 002 series; PDE1 inhbitors - Intra-Cellular Therapies; PDE2 inhibitors - Intra-Cellular Therapies; PDE9 inhibitors - Intra-Cellular TherapiesLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Intra-Cellular Therapies
- Class Small molecules
- Mechanism of Action Phosphodiesterase 9A inhibitors; Type 1 cyclic nucleotide phosphodiesterase inhibitors; Type 2 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Cardiovascular disorders; Neurodegenerative disorders; Schizophrenia
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (PO)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (PO)
- 28 Aug 2022 No recent reports of development identified for research development in Alzheimer's-disease in USA (PO)